Advertisement

Does Gender Affirming Hormone Therapy Increase the Risk of Kidney Disease?

      Summary

      Kidney health and manifestation of disease in transgender men, women, and nonbinary individuals are not well understood. Transgender individuals commonly receive gender-affirming hormone therapy (GAHT) to align their outward appearance with their gender. Recent attention to the differences in fundamental kidney parameters has identified that transgender individuals may manifest levels of these biomarkers differently than their cisgender counterparts. Improving understanding of the differences in biomarkers and in the development of kidney disease is essential to providing appropriate kidney care to this vulnerable population. In this review, we introduce the current information related to GAHT and kidney health and highlight the significant gaps in our understanding of how GAHT may affect kidney physiology and pathophysiology.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Seminars in Nephrology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      REFERENCES

        • Shi M
        • Ma L
        • Zhou L
        • Fu P.
        Renal protective effects of 17β-estradiol on mice with acute aristolochic acid nephropathy. LID - 1391.
        Molecules. 2016; 21: 1391.https://doi.org/10.3390/molecules21101391
        • Aufhauser Jr, DD
        • Wang Z
        • Murken DR
        • et al.
        Improved renal ischemia tolerance in females influences kidney transplantation outcomes.
        J Clin Invest. 2016; 126: 1968-1977https://doi.org/10.1172/jci84712
        • Jotova I
        • Wang C
        • Tabib A
        • Dimitrov O
        • Bachrach U.
        Effects of testosterone and 17, beta-estradiol on the polyamine metabolism in cultivated normal rat kidney epithelial cells.
        Amino Acids. 2000; 18: 353-361https://doi.org/10.1007/pl00010322
        • Kang KP
        • Lee JE
        • Lee AS
        • et al.
        Effect of gender differences on the regulation of renal ischemia‑reperfusion‑induced inflammation in mice.
        Mol Med Rep. 2014; 9: 2061-2068https://doi.org/10.3892/mmr.2014.2089
        • Centers for Disease Control
        Chronic kidney disease in the United States.
        2021 (Accessed October 15, 2021)
        • Ricardo AC
        • Yang W
        • Sha D
        • et al.
        Sex-related disparities in CKD progression.
        J Am Soc Nephrol. 2019; 30: 137-146https://doi.org/10.1681/asn.2018030296
      1. How many adults identify as transgender in the United States? The Williams Institute. Accessed April 26, 2021. https://williamsinstitute.law.ucla.edu/publications/trans-adults-united-states

        • Johns MM
        • Lowry R
        • Andrzejewski J
        • et al.
        Transgender identity and experiences of violence victimization, substance use, suicide risk, and sexual risk behaviors among high school students—19 states and large urban school districts, 2017.
        MMWR Morb Mortal Wkly Rep. 2019; 68: 67-71
        • Schnarrs PW
        • Stone AL
        • Salcido Jr, R
        • Baldwin A
        • Georgiou C
        • Nemeroff CB
        Differences in adverse childhood experiences (ACEs) and quality of physical and mental health between transgender and cisgender sexual minorities.
        J Psychiatr Res. 2019; 119: 1-6https://doi.org/10.1016/j.jpsychires.2019.09.001
        • Ozieh MN
        • Garacci E
        • Campbell JA
        • Walker RJ
        • Egede LE.
        Adverse childhood experiences and decreased renal function: impact on all-cause mortality in U.S. adults.
        Am J Prev Med. 2020; 59: e49-e57https://doi.org/10.1016/j.amepre.2020.04.005
        • Ferrucci KA
        • Lapane KL
        • Jesdale BM
        Prevalence of diagnosed eating disorders in US transgender adults and youth in insurance claims.
        Int J Eat Disord. 2022; 55: 801-809https://doi.org/10.1002/eat.23729
        • Nagata JM
        • Ganson KT
        • Austin SB.
        Emerging trends in eating disorders among sexual and gender minorities.
        Curr Opin Psychiatry. 2020; 33: 562-567https://doi.org/10.1097/yco.0000000000000645
        • Sachs K
        • Mehler PS.
        Medical complications of bulimia nervosa and their treatments.
        Eat Weight Disord. 2016; 21: 13-18https://doi.org/10.1007/s40519-015-0201-4
        • Bouquegneau A
        • Dubois BE
        • Krzesinski JM
        • Delanaye P.
        Anorexia nervosa and the kidney.
        Am J Kidney Dis. 2012; 60: 299-307https://doi.org/10.1053/j.ajkd.2012.03.019
        • Pregnall AM
        • Churchwell AL
        • Ehrenfeld JM.
        A call for LGBTQ content in graduate medical education program requirements.
        Acad Med. 2021; 96: 828-835https://doi.org/10.1097/acm.0000000000003581
        • Bonvicini KA.
        LGBT healthcare disparities: what progress have we made?.
        Patient Educ Couns. 2017; 100: 2357-2361https://doi.org/10.1016/j.pec.2017.06.003
        • Irwig MS.
        Transgender care by endocrinologists in the United States.
        Endocr Pract. 2016; 22: 832-836https://doi.org/10.4158/ep151185.Or
        • Maheshwari A
        • Dines V
        • Saul D
        • Nippoldt T
        • Kattah A
        • Davidge-Pitts C.
        The effect of gender-affirming hormone therapy on serum creatinine in transgender individuals.
        Endocr Pract. 2022; 28: 52-57https://doi.org/10.1016/j.eprac.2021.08.009
        • Millington K
        • Barrera E
        • Daga A
        • et al.
        The effect of gender-affirming hormone treatment on serum creatinine in transgender and gender-diverse youth: implications for estimating GFR.
        Pediatr Nephrol. 2022; 37: 2141-2150https://doi.org/10.1007/s00467-022-05445-0
        • Liu YH
        • Wu TH
        • Chu CH
        • Lin YC
        • Lin LY.
        Metabolic effects of cross-sex hormone therapy in transgender individuals in Taiwan.
        J Chin Med Assoc. 2021; 84: 267-272https://doi.org/10.1097/jcma.0000000000000475
        • Jue JS
        • Alameddine M.
        Evaluation of renal function in transgender patients after gender-affirming hormone therapy.
        Endocr Pract. 2022; 28: 449https://doi.org/10.1016/j.eprac.2021.12.014
        • Collister D
        • Saad N
        • Christie E
        • Ahmed S
        Providing care for transgender persons with kidney disease: a narrative review.
        Can J Kidney Health Dis. 2021; 82054358120985379https://doi.org/10.1177/2054358120985379
        • Jue JS
        • Mikhail D
        • González J
        • Alameddine M.
        Assessment of renal function in transgender patients with kidney disease.
        Can J Kidney Health Dis. 2021; 820543581211020168https://doi.org/10.1177/20543581211020168
        • Collister D
        • Saad N
        • Christie E
        • Ahmed S.
        Response to "assessment of renal function in transgender patients with kidney disease.".
        Can J Kidney Health Dis. 2021; 820543581211020178https://doi.org/10.1177/20543581211020178
      2. Deutsch MB Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People. 2nd ed. University of California, 2016 (Accessed March 2, 2022)
        • Fan S
        • Yeon A
        • Shahid M
        • et al.
        Sex-associated differences in baseline urinary metabolites of healthy adults.
        Sci Rep. 2018; 8: 11883https://doi.org/10.1038/s41598-018-29592-3
        • Tsuji S
        • Sugiura M
        • Tsutsumi S
        • Yamada H.
        Sex differences in the excretion levels of traditional and novel urinary biomarkers of nephrotoxicity in rats.
        J Toxicol Sci. 2017; 42: 615-627https://doi.org/10.2131/jts.42.615
        • Quinn VP
        • Nash R
        • Hunkeler E
        • et al.
        Cohort profile: Study of Transition, Outcomes and Gender (STRONG) to assess health status of transgender people.
        BMJ Open. 2017; 7e018121https://doi.org/10.1136/bmjopen-2017-018121
        • Islam N
        • Nash R
        • Zhang Q
        • et al.
        Is there a link between hormone use and diabetes incidence in transgender people? Data from the STRONG cohort.
        J Clin Endocrinol Metab. 2022; 107: e1549-e1557https://doi.org/10.1210/clinem/dgab832
        • Doublier S
        • Lupia E
        • Catanuto P
        • Elliot SJ.
        Estrogens and progression of diabetic kidney damage.
        Curr Diabetes Rev. 2011; 7: 28-34https://doi.org/10.2174/157339911794273982
      3. HIV Infection, Risk, Prevention, and Testing Behaviors Among Transgender Women—National HIV Behavioral Surveillance, 7 U.S. Cities. 27. 2021: 2019-2020 (HIV Surveillance Special Report 27. Published April 2021. Accessed September 1, 2022.)
        • Stutterheim SE
        • van Dijk M
        • Wang H
        • Jonas KJ.
        The worldwide burden of HIV in transgender individuals: an updated systematic review and meta-analysis.
        PLoS One. 2021; 16e0260063https://doi.org/10.1371/journal.pone.0260063
        • Poteat TC
        • Radix A.
        HIV antiretroviral treatment and pre-exposure prophylaxis in transgender individuals.
        Drugs. 2020; 80: 965-972https://doi.org/10.1007/s40265-020-01313-z
        • Tang EC
        • Vittinghoff E
        • Anderson PL
        • et al.
        Changes in kidney function associated with daily tenofovir disoproxil fumarate/emtricitabine for HIV preexposure prophylaxis use in the United States demonstration project.
        J Acquir Immune Defic Syndr. 2018; 77: 193-198https://doi.org/10.1097/qai.0000000000001566
        • Ascher SB
        • Scherzer R
        • Estrella MM
        • et al.
        HIV preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine and changes in kidney function and tubular health.
        AIDS. 2020; 34: 699-706https://doi.org/10.1097/qad.0000000000002456
        • Reckelhoff JF.
        Gender differences in the regulation of blood pressure.
        Hypertension. 2001; 37: 1199-1208https://doi.org/10.1161/01.hyp.37.5.1199
        • Rossouw JE
        • Anderson GL
        • Prentice RL
        • et al.
        Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial.
        JAMA. 2002; 288: 321-333https://doi.org/10.1001/jama.288.3.321
        • Banks K
        • Kyinn M
        • Leemaqz SY
        • Sarkodie E
        • Goldstein D
        • Irwig MS.
        Blood pressure effects of gender-affirming hormone therapy in transgender and gender-diverse adults.
        Hypertension. 2021; 77: 2066-2074https://doi.org/10.1161/hypertensionaha.120.16839
        • Mehta Y
        • Seal LJ
        • Angus-Leppan H.
        Idiopathic intracranial hypertension in transgender people: case report and best practice.
        J Neuroophthalmol. 2021; https://doi.org/10.1097/wno.0000000000001458
        • Kataoka H
        • Sawara Y
        • Kawachi K
        • Manabe S
        • Mochizuki T
        • Nitta K.
        Impacts of sex differences in pulse pressure among patients with chronic kidney disease.
        J Pers Med. 2019; 9: 52https://doi.org/10.3390/jpm9040052
        • Khurana KK
        • Navaneethan SD
        • Arrigain S
        • Schold JD
        • Nally Jr, JV
        • Shoskes DA
        Serum testosterone levels and mortality in men with CKD stages 3-4.
        Am J Kidney Dis. 2014; 64: 367-374https://doi.org/10.1053/j.ajkd.2014.03.010
        • Yeo JK
        • Koo HS
        • Yu J
        • Park MG.
        Effects of testosterone treatment on quality of life in patients with chronic kidney disease.
        Am J Mens Health. 2020; 141557988320917258https://doi.org/10.1177/1557988320917258
        • Collister D
        • Krakowsky Y
        • Potter E
        • Millar AC.
        Chronic kidney disease in the transgender, nonbinary, or gender diverse person.
        Semin Nephrol. 2022; 42: 129-141https://doi.org/10.1016/j.semnephrol.2022.04.004
        • Eckenrode HE
        • Gutierrez OM
        • Osis G
        • Agarwal A
        • Curtis LM.
        Kidney disease prevalence in transgender individuals.
        Clin J Am Soc Nephrol. 2022; 17: 280-282https://doi.org/10.2215/cjn.04660421
        • Hutchens MP
        • Dunlap J
        • Hurn PD
        • Jarnberg PO
        Renal ischemia: does sex matter?.
        Anesth Analg. 2008; 107: 239-249https://doi.org/10.1213/ane.0b013e318178ca42
        • Nusbaum JS
        • Mirza I
        • Shum J
        • et al.
        Sex differences in systemic lupus erythematosus: epidemiology, clinical considerations, and disease pathogenesis.
        Mayo Clin Proc. 2020; 95: 384-394https://doi.org/10.1016/j.mayocp.2019.09.012
        • Ocon A
        • Peredo-Wende R
        • Kremer JM
        • Bhatt BD
        Significant symptomatic improvement of subacute cutaneous lupus after testosterone therapy in a female-to-male transgender subject.
        Lupus. 2018; 27: 347-348https://doi.org/10.1177/0961203317734921
        • Pontes LT
        • Camilo DT
        • De Bortoli MR
        • Santos RSS
        • Luchi WM
        New-onset lupus nephritis after male-to-female sex reassignment surgery.
        Lupus. 2018; 27: 2166-2169https://doi.org/10.1177/0961203318800571
        • Zerres K
        • Rudnik-Schöneborn S
        • Deget F
        • et al.
        Autosomal recessive polycystic kidney disease in 115 children: clinical presentation, course and influence of gender. Arbeitsgemeinschaft für Pädiatrische, Nephrologie.
        Acta Paediatr. 1996; 85: 437-445https://doi.org/10.1111/j.1651-2227.1996.tb14056.x
        • Talbi K
        • Cabrita I
        • Schreiber R
        • Kunzelmann K.
        Gender-dependent phenotype in polycystic kidney disease is determined by differential intracellular Ca(2+) signals.
        Int J Mol Sci. 2021; 22: 6019https://doi.org/10.3390/ijms22116019
        • Gretz N
        • Ceccherini I
        • Kränzlin B
        • et al.
        Gender-dependent disease severity in autosomal polycystic kidney disease of rats.
        Kidney Int. 1995; 48: 496-500https://doi.org/10.1038/ki.1995.319
        • Luan R
        • Tian G
        • Zhang H
        • et al.
        Urinary exosomal circular RNAs of sex chromosome origin are associated with gender-related risk differences of clinicopathological features in patients with IgA nephropathy.
        J Nephrol. 2022; 35: 1069-1078https://doi.org/10.1007/s40620-021-01118-7
        • Deng W
        • Tan X
        • Zhou Q
        • et al.
        Gender-related differences in clinicopathological characteristics and renal outcomes of Chinese patients with IgA nephropathy.
        BMC Nephrol. 2018; 19: 31https://doi.org/10.1186/s12882-018-0829-1
        • Riispere Ž
        • Laurinavičius A
        • Kuudeberg A
        • et al.
        IgA nephropathy clinicopathologic study following the Oxford classification: progression peculiarities and gender-related differences.
        Medicina (Kaunas). 2016; 52: 340-348https://doi.org/10.1016/j.medici.2016.11.003
        • Durant B
        • Forni S
        • Sweetman L
        • et al.
        Sex differences of urinary and kidney globotriaosylceramide and lyso-globotriaosylceramide in Fabry mice.
        J Lipid Res. 2011; 52: 1742-1746https://doi.org/10.1194/jlr.M017178
        • Ferraro PM
        • Cunha TDS
        • Curhan GC.
        Sex differences and the risk of kidney stones.
        Semin Nephrol. 2022; 42: 230-235https://doi.org/10.1016/j.semnephrol.2022.04.012
        • Whitley CT
        • Greene DN.
        Transgender man being evaluated for a kidney transplant.
        Clin Chem. 2017; 63: 1680-1683https://doi.org/10.1373/clinchem.2016.268839
        • Buxeda A
        • Redondo-Pachón D
        • Pérez-Sáez MJ
        • Crespo M
        • Pascual J.
        Sex differences in cancer risk and outcomes after kidney transplantation.
        Transplant Rev (Orlando). 2021; 35100625https://doi.org/10.1016/j.trre.2021.100625
        • Ramadan OI
        • Naji A
        • Levine MH
        • et al.
        Kidney transplantation and donation in the transgender population: a single-institution case series.
        Am J Transplant. 2020; 20: 2899-2904https://doi.org/10.1111/ajt.15963
        • Judge C
        • O'Donovan C
        • Callaghan G
        • Gaoatswe G
        • O'Shea D
        Gender dysphoria - prevalence and co-morbidities in an irish adult population.
        Front Endocrinol (Lausanne). 2014; 5: 87https://doi.org/10.3389/fendo.2014.00087